logo
Share SHARE
FONT-SIZE Plus   Neg

BioMarin Reports Encouraging Data In Hemophilia A Gene Therapy Program

BioMarin Pharmaceutical Inc. (BMRN) announced encouraging preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational gene therapy treatment for hemophilia A.

The company said that a total of eight patients with severe hemophilia A received a single dose of BMN 270, six of whom have been treated at the highest dose of 6 x 1013 vg/kg, and to date, post-treatment follow-up ranges from five to 16 weeks.

Patients with hemophilia A are not able to produce enough functional Factor VIII to prevent bleeding, and are currently treated with prophylactic or on-demand infusions of plasma-derived or recombinant Factor VIII.

At last observation, patients at the highest dose experienced increasing Factor VIII activity levels ranging between 4 and 60 percent, with five of six patients treated at the high dose showing factor VIII levels above 5 percent and two of six showing increasing levels of factor VIII at over 50 percent.

All the high dose patients improved from severe to either moderate, mild or normal range in terms of factor levels based on World Federation of Hemophilia criteria.

"We are encouraged by this early data on BMN 270 and the trend we are seeing in increasing Factor VIII levels over time. BMN 270 could have the potential to reduce and possibly eliminate the need for infusions of Factor VIII," said Hank Fuchs, Chief Medical Officer at BioMarin.

BioMarin plans to discuss these findings with UK regulatory authorities prior to dosing the remaining patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Aerospace and defense major Boeing's shares increased in the extended trading on Monday after the company announced a 20 percent increase in quarterly dividend and also boosted its share repurchase program to $18 billion, citing its strong and growing cash flow. Checkout the companies that are expected to release quarterly financial results on Tuesday, December 12, 2017. * ARWR to benefit from collaboration agreement with Amgen * Demand for PoS software, PaaS technologies to propel PAY Q4 Two major hospitals Ascension Health and Providence St. Joseph Health are in discussion for merger to create one of the largest hospital chain, reported Wall Street Journal. The combination is expected to have 191 hospitals with an annual revenue of around $45 billion. The new entity would dethrone America's largest hospital operator Hospital Corporation of America that owns 177 hospitals and reve
comments powered by Disqus
Follow RTT